Peptide Decoding
News

Is Wegovy Approved for Kids Under 12? What STEP Young Actually Shows

By Allison Thorne · Editorial standards
Published November 21, 2026
A folded teal child's shirt, a stethoscope and a small glass vial on a white clinical surface.

No. As of November 18, 2026, semaglutide, the drug in Wegovy and Ozempic, is not approved in the US for anyone under 12. On November 16, the first phase 3 trial of it in children aged 6 to 11, the large final stage of testing before approval, was published in the New England Journal of Medicine.12 Over 68 weeks, BMI fell 13.5% on weekly semaglutide and rose 2.7% on placebo, a difference of 16.2 percentage points in 167 children.1

The effect was more than twice what daily liraglutide managed in an earlier trial at the same ages, and close to semaglutide's result in teenagers. Novo's headline figures come from an analysis that assumes every child stayed on treatment, though, and by week 104 the children on the drug had given back part of their BMI drop.2 Novo has not announced a filing to extend the label to younger children.2

Our guide to GLP-1 drugs in teenagers said nothing in this class was approved for weight below age 12 anywhere in the world. That line was wrong. The European Union extended liraglutide, sold as Saxenda, to children from age 6 in 2025, and the guide is being corrected.3

What did STEP Young test?

STEP Young tested once-weekly semaglutide injections against placebo in elementary-school-age children with obesity, and every child in both groups also got lifestyle counseling.1 Children were randomized two to one, 112 to semaglutide and 55 to placebo. More than 85% started in class II or III obesity, the two most severe of the three bands pediatricians use.12

Treatment ran 104 weeks, followed by seven weeks off the drug. The primary endpoint, the single result a trial is designed and powered to test, was the percent change in BMI at week 68.1 Doses were capped by starting weight: up to 2.4 mg a week for children over about 132 pounds, and up to 1.7 mg for those between about 99 and 132 pounds, or the highest dose a child tolerated.12 Adults on Wegovy go up to 2.4 mg, so the heaviest children reached the adult maximum.

The trial is registered as NCT05726227.4 Novo describes it as part of the post-marketing requirements regulators attached to semaglutide, meaning a study the company was obliged to run after the adult and adolescent approvals.5 The September topline counted 165 children and the published paper counts 167.561 This page uses the paper's figure.

What did the trial find?

The trial met its primary endpoint. At week 68 BMI fell 13.5% on semaglutide and rose 2.7% on placebo, an estimated difference of 16.2 percentage points.1

The other results point the same way. Children on the drug were far more likely to move down at least one BMI category, 79% against 23%. Of those on semaglutide, 38% were no longer in the obesity range at week 68, against 2% on placebo.1 For a child, the obesity range means a BMI at or above the 95th percentile for age and sex on the CDC growth charts.5

All of these are BMI figures because the children are still growing, and a child who holds weight steady while getting taller ends up with a lower BMI. Body weight results were not in the published summaries of the paper.1

How does it compare with the earlier trials?

It more than doubles the effect of the earlier phase 3 liraglutide trial in this age group and lands near semaglutide's result in teenagers. That earlier trial, SCALE Kids, tested daily liraglutide in 82 children of the same ages for 56 weeks and was published in NEJM in September 2024.7

SCALE Kids STEP Young STEP TEENS
Drug Liraglutide, daily Semaglutide, weekly Semaglutide, weekly
Ages 6 to under 12 6 to under 12 12 to under 18
Children randomized 82 167 201
Primary time point 56 weeks 68 weeks 68 weeks
BMI on the drug 5.8% lower 13.5% lower 16.1% lower
BMI on placebo 1.6% higher 2.7% higher 0.6% higher
Gap between groups 7.4 points 16.2 points 16.7 points

These are separate trials with different lengths, not a head-to-head comparison.1768 The STEP TEENS gap is our arithmetic from its two group figures. Even with those limits, weekly semaglutide moved BMI about twice as far as daily liraglutide did in children of the same ages.

SCALE Kids also shows why BMI is the measure. Body weight on liraglutide still rose 1.6% over the year while weight on placebo rose 10%, and BMI fell anyway because the children grew.7

Why are Novo's numbers bigger than the paper's?

Novo leads with a different analysis. Trials like this report two estimands, two defined ways of asking what a drug did. The treatment-regimen estimand counts every child as randomized, including those who stopped or missed doses, and it is the paper's primary result. The efficacy estimand estimates what would have happened if every child had stayed on treatment as planned.12

At week 68 Treatment regimen (every child) Efficacy (if all stayed on the drug)
BMI change, semaglutide 13.5% lower 17.4% lower
BMI change, placebo 2.7% higher 2.2% higher
No longer in the obesity range 38.4% vs 2.1% 40.4% vs 0%
BMI down by 10% or more 74.7% vs 4.3% 78.7% vs 0%

Novo's November headline, a 10% or greater BMI reduction in almost 80% of children, uses the efficacy column.2 So did its September headline of 40% below the obesity threshold with none on placebo.5 The paper's summary adds that the 10% figure comes from a supportive endpoint not adjusted for multiple comparisons. A trial that runs many tests will hit a few by chance, and an unadjusted result has not been corrected for that, so it counts as weaker evidence than the primary one.1

Neither analysis is a trick. The efficacy figure tells you what the drug can do in a child who takes every dose. The treatment-regimen figure is closer to what a family would see, because real children stop and miss doses too.

What happened by week 104?

The children on semaglutide gave back part of their drop while the placebo group kept climbing. At week 104, BMI was 9.4% below baseline on semaglutide and 8.4% above it on placebo, a gap of 17.8 points.12

The gap between groups held, and even widened a little. The drop on semaglutide itself shrank from 13.5% to 9.4% while children were still taking it, though, and no published summary explains why. Children keep growing through these years, and the placebo group's 8.4% rise over two years shows how strongly BMI climbs in this group without treatment. Novo labels the week-104 results as supportive secondary endpoints that were not adjusted for multiplicity.2

Results from the seven weeks off the drug have not been reported yet. In STEP TEENS, weight was already coming back in the seven weeks after treatment ended, so that number matters.8

Is semaglutide safe for children this young?

Novo says the trial found no safety concerns for growth or pubertal development, and calls the overall profile "consistent with previous Novo pediatric and adult trials."2 Adverse events of any kind were reported in 96% of children on semaglutide and 93% on placebo. Gastrointestinal effects such as nausea, vomiting and diarrhea were the most common and more frequent on the drug, and they led one child to stop treatment.1

That is reassuring, and it covers two years of treatment. The paper's own summary says longer data on growth, puberty and what happens after stopping are still needed.1 Serious adverse events and gallbladder problems were not in the published summaries. In STEP TEENS, five adolescents on semaglutide developed gallbladder disease with gallstones against none on placebo, so that is the line to look for in the full paper.8

Fewer children stopped than in the liraglutide trial at the same ages. In SCALE Kids, 80.4% of children on liraglutide had gastrointestinal side effects against 53.8% on placebo, and 10.7% stopped because of side effects of any kind against none on placebo.7 STEP Young's one discontinuation counts gastrointestinal effects only, so the two figures do not measure exactly the same thing.1

What do pediatric guidelines say about drugs at these ages?

Both major guidelines currently stop short of most of the children in this trial. The World Health Organization's first guidelines on child obesity, published in October 2026, do not recommend medication for children aged 0 to 9. For ages 10 to 19, WHO says approved medicines may be considered only after a supervised lifestyle program has not worked.8 The American Academy of Pediatrics' 2023 guideline says clinicians should offer medication alongside lifestyle treatment from age 12.8

So STEP Young's 6- to 9-year-olds fall in the age band WHO currently recommends against treating with drugs, and its 10- and 11-year-olds sit below the AAP's starting age. Neither guideline had these results to weigh, since WHO's was published a month before the paper. Until they change, a pediatrician who prescribes semaglutide at these ages is working off-label, meaning outside the uses the FDA approved, and outside current guidance.

The case on the other side is real. More than 85% of these children already had severe obesity.12 Valerie O'Hara, a pediatric weight management physician writing in Healio after the topline, put the case for treating them as "Waiting is not treatment," and called medication an evidence-based part of care, not a sign of failure.6

Is any GLP-1 drug approved for children under 12?

Not in the US. Novo's release states that semaglutide injection "is not approved in the United States for use in children under the age of 12."2 Saxenda's US approval for weight also starts at 12. Ozempic and Mounjaro, the diabetes brands of semaglutide and tirzepatide, carry no pediatric weight indication, and Zepbound has no pediatric approval at all.8

In the European Union, one is. On May 22, 2025, the European Medicines Agency's medicines committee recommended extending Saxenda to children aged 6 to under 12 with obesity who weigh at least about 99 pounds.3 The same recommendation says treatment should stop and be re-evaluated if a child has not lost at least 4% of BMI after 12 weeks at the full or highest tolerated dose.3 The agency's product page now lists the indication for "children from the age of 6 to <12 years with obesity (BMI ≥95th percentile)."9

Will Wegovy be approved for younger children?

Possibly, though no filing has been announced. Neither the September topline nor the November release mentions an FDA or European submission for this age group, and the November release says there is no guarantee semaglutide will become commercially available for the uses under investigation.25 Trade coverage of the topline said the result could support a future label expansion to children as young as six.4

The liraglutide record gives a rough sense of pace in Europe. SCALE Kids was published in September 2024 and the European committee's recommendation followed in May 2025.73 Nothing comparable has been dated for semaglutide.

What is known, and what is not?

What STEP Young shows:

  • Weekly semaglutide lowered BMI by 16.2 points more than placebo at 68 weeks in children aged 6 to 11, counting every child randomized.1
  • Most children on the drug moved down at least one BMI category, and about four in ten left the obesity range.12
  • The gap over placebo was still there at 104 weeks.1
  • Side effects were mostly gastrointestinal, and only one child stopped because of them.1
  • Novo reports no safety concerns for growth or puberty over two years.2

What it does not show yet:

  • Body weight, serious adverse events and gallbladder events. None were in the published summaries.1
  • What happened in the seven weeks after children stopped.
  • Why the BMI drop on the drug shrank between weeks 68 and 104.
  • Effects on growth, puberty and bone beyond two years. The paper itself says these still need study.1
  • When, or whether, Novo will file for this age group.2

Does this change anything for someone using semaglutide now?

For adults, it changes very little. STEP Young used pharmaceutical semaglutide, dosed by body weight and monitored for growth and puberty over two years, and a pediatric trial says nothing about what is in a gray-market vial.12 Our semaglutide page covers the adult evidence and the approved labels.

If you are a parent and your child's pediatrician has raised this, you now have a real trial to ask about, and a short list of questions it cannot answer yet: what happens past two years, what happens after stopping, and why the effect faded in year two. The children in the trial also had lifestyle counseling alongside the drug, and both guidelines build medication around a lifestyle program. Our guide to GLP-1 drugs in teenagers covers what that program involves and how WHO and the AAP disagree about its timing.

Common questions

Is Wegovy approved for children under 12?

No. In the US, Wegovy is approved for weight from age 12. STEP Young is the trial that could support a younger label, and Novo has not announced a filing.

What is STEP Young?

A phase 3 trial of weekly semaglutide against placebo in 167 children aged 6 to under 12 with obesity. Novo Nordisk ran it, and the results were published in the New England Journal of Medicine on November 16, 2026, and presented at ObesityWeek the same week.

How much did BMI drop in children on semaglutide?

By 13.5% at week 68, against a 2.7% rise on placebo, counting every child randomized. The gap was 16.2 percentage points.

Why does Novo say almost 80% of children cut BMI by 10%?

Because that figure assumes every child stayed on treatment. Counting all children as randomized, the figure was 74.7% against 4.3% on placebo, and the paper treats it as supportive evidence only.

What does "no longer classified as having obesity" mean?

A BMI that dropped below the 95th percentile for age and sex on the CDC growth charts. That happened for 38.4% of children on semaglutide and 2.1% on placebo at week 68.

Did the effect last for two years?

Partly. At week 104 BMI was 9.4% below baseline on semaglutide, down from 13.5% at week 68. Placebo BMI rose 8.4%, so the gap between groups held.

What side effects did the children have?

Mostly gastrointestinal ones, such as nausea, vomiting and diarrhea. Adverse events of any kind were reported in 96% on semaglutide and 93% on placebo, and one child stopped because of gastrointestinal effects.

Did semaglutide affect growth or puberty?

Not that the trial found. Novo reports no safety concerns for growth or pubertal development over two years, and the paper says longer data are still needed.

How does semaglutide compare with liraglutide in children?

It moved BMI about twice as far, though the trials were run separately. In SCALE Kids, liraglutide lowered BMI by 5.8% against a 1.6% rise on placebo over 56 weeks.

Were the children given adult doses?

Some were. The trial capped the dose by starting weight: up to 2.4 mg a week above about 132 pounds and up to 1.7 mg between about 99 and 132 pounds, or the highest dose tolerated.

When will Wegovy be approved for kids aged 6 to 11?

Unknown. No FDA or European filing has been announced, and no date has been given.

Is Saxenda approved for children under 12?

In the European Union, yes, from age 6 for children with obesity who weigh at least about 99 pounds. In the US, Saxenda's weight approval starts at 12.

Is Ozempic approved for kids?

No. Ozempic is semaglutide's diabetes brand and carries no pediatric weight indication. Wegovy is the weight brand, approved from age 12 in the US.

Do pediatric guidelines recommend weight-loss drugs for children under 12?

Not at present. WHO does not recommend medication for children aged 0 to 9, and the AAP guideline starts at 12. Both were written without STEP Young's results.

Is tirzepatide approved for children?

No. Zepbound has no pediatric approval, so a child or teenager on tirzepatide is taking it off-label.

What happened when children stopped semaglutide?

Not yet reported. The trial included seven weeks off the drug after week 104, and those results have not been published in any summary so far.

Where can I read the trial?

In the New England Journal of Medicine, published November 16, 2026, under DOI 10.1056/NEJMoa2604058. The trial registration is NCT05726227.

Sources

  1. Contemporary Pediatrics. Semaglutide cuts BMI 13.5% in children aged 6 to 11 with obesity. November 16, 2026. contemporarypediatrics.com.
    Read via a reproduction: an independent report of the STEP Young paper in the New England Journal of Medicine (DOI 10.1056/NEJMoa2604058). We could not open the paper directly. Source of the design, the treatment-regimen results at weeks 68 and 104, the adverse event rates, the note that the 10% figure is a multiplicity-unadjusted supportive endpoint, and the paper's statement that longer data on growth, puberty and durability are needed. It does not report body weight, serious adverse events or gallbladder events. ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩
  2. Novo Nordisk. Wegovy resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12. November 16, 2026. novonordisk.com.
    Read at source. Company document, not independent confirmation. Gives both estimands at weeks 68 and 104, the weight-based dose caps, the statement of no safety concerns for growth or pubertal development, and the statement that semaglutide is not approved in the US under age 12. Mentions no regulatory submission. ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩
  3. European Medicines Agency. Saxenda (liraglutide), extension of indication. CHMP opinion of May 22, 2025. ema.europa.eu.
    Read at source. Regulator document. Recommends extending the indication to children aged 6 to less than 12 years with obesity and a body weight of at least about 99 pounds (the document states the threshold in kilograms), with treatment stopped and re-evaluated if BMI or BMI z-score has not fallen at least 4% after 12 weeks. ↩ ↩ ↩ ↩
  4. Clinical Trials Arena. Novo's Wegovy touts obesity-treating potential in patients as young as six. September 8, 2026. clinicaltrialsarena.com.
    Read at source. Independent trade reporting of the topline. Source of the registration number NCT05726227 and the comment that the result could support a future label expansion. Describes no filing. ↩ ↩
  5. Novo Nordisk. 40 percent of children living with obesity achieved a BMI below the obesity threshold with semaglutide. September 8, 2026. novonordisk.com.
    Read at source. Company topline release, not independent confirmation; the page carries no date, and the date is taken from same-day coverage. Reports 165 children, the 40.4% efficacy-estimand figure, the CDC 95th percentile definition, and that the trial runs under regulators' post-marketing requirements. ↩ ↩ ↩ ↩ ↩
  6. Healio. Injectable Wegovy lowers BMI among children with obesity. September 8, 2026. healio.com.
    Read at source. Independent reporting of the topline, with a perspective by Valerie M. O'Hara, DO, FAAP, a pediatric weight management physician, who reports no relevant financial disclosures; source of the quoted "Waiting is not treatment". Confirms the 165-child topline count, describes STEP Young as the first phase 3 semaglutide trial in children under 12, and gives the STEP TEENS result of a 16.1% BMI reduction at 68 weeks. ↩ ↩ ↩
  7. News-Medical. Obesity medication liraglutide safe and effective in children under 12, research finds. September 10, 2024. news-medical.net.
    Read via a reproduction: a report of the SCALE Kids paper in the New England Journal of Medicine (DOI 10.1056/NEJMoa2407379). We did not open the paper. Source of the 82 children, 56 weeks, BMI and body weight changes, gastrointestinal event rates and discontinuations. ↩ ↩ ↩ ↩ ↩
  8. Peptide Decoding. Are GLP-1 Drugs Safe for Teenagers? What the Trials Did Not Measure. Updated October 18, 2026. peptidedecoding.com.
    Our own earlier page. It cites the STEP TEENS paper and the US labels. Source of the STEP TEENS placebo figure, the gallbladder cases, the weight returning between weeks 68 and 75, Saxenda's US approval from age 12, the absence of a pediatric weight indication for Ozempic and Mounjaro, and Zepbound's adult-only approval. Also the source of the WHO October 2026 child and adolescent obesity guidelines (no medication recommended for ages 0 to 9; medicines considered for ages 10 to 19 only after a supervised lifestyle program) and the American Academy of Pediatrics 2023 guideline (medication offered alongside lifestyle treatment from age 12), both of which that page read at source; we did not re-read them for this piece. Its line saying nothing in the class is approved under 12 anywhere is wrong for the European Union and is being corrected. ↩ ↩ ↩ ↩ ↩ ↩
  9. European Medicines Agency. Saxenda: EPAR, medicine overview. Page last updated July 31, 2025. ema.europa.eu.
    Read at source. Regulator document. Source of the quoted indication wording for children aged 6 to under 12. ↩

Citing this page. Peptide Decoding. Is Wegovy Approved for Kids Under 12? What STEP Young Actually Shows. Trial figures from the STEP Young paper published in NEJM on November 16, 2026, as reported, and Novo Nordisk's releases of September 8 and November 16, 2026; European approval from the EMA's May 22, 2025 opinion on Saxenda. Reviewed November 19, 2026. https://peptidedecoding.com/news/semaglutide-children-step-young